Norovirus Vaccine - Vaxart

Drug Profile

Norovirus Vaccine - Vaxart

Alternative Names: H1N1 (high dose) Oral Vaccine Tablet; H1N1 (low dose) Oral Vaccine Tablet; VXA-G1-1-NN; VXA-G1.1-NN

Latest Information Update: 07 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vaxart
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Norovirus infections

Most Recent Events

  • 06 May 2018 Vaxart completes a phase I trial in Healthy volunteers in USA (NCT03125473)
  • 03 Nov 2017 Immunogenicity data from a phase Ib trial in Healthy volunteers released by Vaxart
  • 30 Oct 2017 Vaxart plans a phase II norovirus challenge study in Q2 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top